Chiesi Group is acquiring KalVista Pharmaceuticals for $27 per share in cash, representing a total value of approximately $1.9 billion1
The acquisition includes Ekterly (sebetralstat), the first oral, on-demand plasma kallikrein inhibitor approved by the FDA for treating acute hereditary angioedema (HAE) attacks in patients 12 years and older1
Ekterly received FDA approval in July 2025 and generated $49.1 million in sales in 20251
The deal terms represent a 36% premium on KalVista's 30-day average share price1
The transaction is expected to close in the third quarter of 20262
This is Chiesi's most substantial acquisition to date in value terms1
Hereditary angioedema is a rare genetic disorder causing days-long swelling attacks that can be extremely painful and life-threatening1
Ekterly is the only on-demand treatment among competing HAE therapies; other options like Ionis' Dawnzera and CSL's Andembry are injectable prophylactic drugs administered regularly1
Sources:
1. https://www.biospace.com/business/chiesi-snaps-up-kalvista-for-1-9b-betting-big-on-rare-disease-med-ekterly
2. https://www.biospace.com/press-releases/chiesi-group-to-acquire-kalvista-pharmaceuticals-expanding-its-global-rare-disease-portfolio